6945 Stock Overview
AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AP Biosciences Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$60.80 |
| 52 Week High | NT$84.20 |
| 52 Week Low | NT$41.05 |
| Beta | 0 |
| 1 Month Change | -0.16% |
| 3 Month Change | 10.95% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6945 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 6.1% | 0.7% | 1.3% |
| 1Y | n/a | -24.2% | 29.2% |
Return vs Industry: Insufficient data to determine how 6945 performed against the TW Biotechs industry.
Return vs Market: Insufficient data to determine how 6945 performed against the TW Market.
Price Volatility
| 6945 volatility | |
|---|---|
| 6945 Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6945 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6945's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 37 | Jeng-Horng Her | www.apbioinc.com |
AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. The company was founded in 2013 and is based in Taipei City, Taiwan.
AP Biosciences Inc Fundamentals Summary
| 6945 fundamental statistics | |
|---|---|
| Market cap | NT$3.94b |
| Earnings (TTM) | -NT$339.29m |
| Revenue (TTM) | NT$32.25m |
122.1x
P/S Ratio-11.6x
P/E RatioIs 6945 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6945 income statement (TTM) | |
|---|---|
| Revenue | NT$32.25m |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$32.25m |
| Other Expenses | NT$371.55m |
| Earnings | -NT$339.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.24 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,051.98% |
| Debt/Equity Ratio | 0% |
How did 6945 perform over the long term?
See historical performance and comparison